Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators

…, Y Kawakami, K Arihiro, H Ohdan, K Gotoh… - Nature …, 2012 - nature.com
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death
worldwide. We sequenced and analyzed the whole genomes of 27 HCCs, 25 of which were …

Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer

…, H Taniguchi, Y Kawakami, M Ueno, K Gotoh… - Nature …, 2016 - nature.com
Liver cancer, which is most often associated with virus infection, is prevalent worldwide, and
its underlying etiology and genomic structure are heterogeneous. Here we provide a whole-…

Inhibition of autophagy prevents hippocampal pyramidal neuron death after hypoxic-ischemic injury

M Koike, M Shibata, M Tadakoshi, K Gotoh… - The American journal of …, 2008 - Elsevier
Neonatal hypoxic/ischemic (H/I) brain injury causes neurological impairment, including
cognitive and motor dysfunction as well as seizures. However, the molecular mechanisms …

A novel image‐guided surgery of hepatocellular carcinoma by indocyanine green fluorescence imaging navigation

K Gotoh, T Yamada, O Ishikawa… - Journal of surgical …, 2009 - Wiley Online Library
Background and Objectives The clear delineation between tumor and normal tissue is ideal
for real‐time surgical navigation imaging. We present a novel indocyanine green (ICG) …

[HTML][HTML] Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations

…, Y Kawakami, H Aikata, M Ueno, S Hayami, K Gotoh… - Journal of …, 2018 - Elsevier
Background & Aims Biliary tract cancers (BTCs) are clinically and pathologically heterogeneous
and respond poorly to treatment. Genomic profiling can offer a clearer understanding of …

Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial

…, K Shimada, Y Takahashi, T Nakagohri, K Gotoh… - The Lancet, 2023 - thelancet.com
Background S-1 has shown promising efficacy with a mild toxicity profile in patients with
advanced biliary tract cancer. The aim of this study was to evaluate whether adjuvant S-1 …

[HTML][HTML] MicroRNA-155 controls exosome synthesis and promotes gemcitabine resistance in pancreatic ductal adenocarcinoma

…, T Asaoka, T Noda, H Wada, K Kawamoto, K Gotoh… - Scientific reports, 2017 - nature.com
The cancer drug gemcitabine (GEM) is a key drug for treating pancreatic ductal adenocarcinoma
(PDAC), but PDAC cells develop chemoresistance after long-term administration. Since …

Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis

…, C Tamai, R Ishihara, T Matsunaga, K Gotoh… - Journal of …, 2009 - Springer
Purpose Characteristics of hepatocellular carcinoma (HCC) complicating nonalcoholic
steatohepatitis (NASH) are still controversial. Most NASH related HCCs are believed to develop …

LC3, an autophagosome marker, is highly expressed in gastrointestinal cancers

…, M Yamasaki, I Sohma, K Gotoh… - International …, 2008 - spandidos-publications.com
Autophagy is a bulk protein and organelle degradation process essential for cell maintenance
and viability. Microtubule-associated protein 1 light chain 3 (LC3), the mammalian …

[HTML][HTML] Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity

A Fujimoto, M Furuta, Y Shiraishi, K Gotoh… - Nature …, 2015 - nature.com
Intrahepatic cholangiocarcinoma and combined hepatocellular cholangiocarcinoma show
varying degrees of biliary epithelial differentiation, which can be defined as liver cancer …